Combination treatment with interferon (IFN) and ribavirin (RBV) for hepatitis C (HCV) in HIV co-infection patients.

被引：0
|
作者：
Dieterich, DT
Weisz, KB
Goldman, DJ
Malicdem, ML
机构：
[1] Cabrini Med Ctr, New York, NY USA
[2] Liberty Med LLP, New York, NY USA
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
422
引用
收藏
页码：266A / 266A
页数：1
相关论文
共 50 条
  • [21] Erythropoictic response to anemia is decreased in patients infected with hepatitis C virus (HCV) receiving combination ribavirin and pegylated interferon (RBV/PEG-IFN) therapy
    Balan, V
    Wu, GY
    Muir, AJ
    Keeffe, EB
    Bowers, PJ
    GASTROENTEROLOGY, 2003, 124 (04) : A751 - A751
  • [22] HIV and hepatitis C co-infection: acute HCV therapy
    Boesecke, Christoph
    Vogel, Martin
    CURRENT OPINION IN HIV AND AIDS, 2011, 6 (06) : 459 - 464
  • [23] Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection
    Graham, CS
    Wells, A
    Liu, T
    Sherman, KE
    Peters, M
    Chung, RT
    Bhan, AK
    Andersen, J
    Koziel, MJ
    AIDS, 2006, 20 (03) : 345 - 351
  • [24] Treatment of chronic hepatitis c with peginterferon alfa-2A (400) (PEG) and ribavirin (RBV) in naive patients with HIV-HCV co-infection in the real-life setting in germany
    Zehnter, Elmor
    Mauss, Stefan
    Boeker, Klaus
    Lutz, Thomas
    Racky, Stefan
    Schmidt, Wolfgang
    Ullrich, Rainer
    Sbrijer, Innesso
    Heyne, Renate
    Schober, Andreas
    John, Christine
    Hey, Karl-Heinz
    Moeller, Bernd
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Pape, Stefan
    Alshuth, Ulrich
    Hueppe, Dietrich
    HEPATOLOGY, 2007, 46 (04) : 362A - 362A
  • [25] Treatment of acute HCV infection in HIV co-infection: Influence of HCV genotype and ribavirin upon treatment outcome
    Boesecke, Christoph
    Ingiliz, Patrick
    Stellbrink, Hans-Juergen
    Nelson, Mark
    Page, Emma E.
    Bhagani, Sanjay
    Guiguet, Marguerite
    Valantin, Marc-Antoine
    Reiberger, Thomas
    Vogel, Martin
    Rockstroh, Juergen K.
    HEPATOLOGY, 2012, 56 : 215A - 215A
  • [26] Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection
    Grebely, Jason
    Hellard, Margaret
    Applegate, Tanya
    Petoumenos, Kathy
    Yeung, Barbara
    Feld, Jordan J.
    Rawlinson, William
    Lloyd, Andrew R.
    George, Jacob
    Kaldor, John M.
    Dore, Gregory J.
    Matthews, Gail V.
    AIDS, 2012, 26 (13) : 1653 - 1661
  • [27] Treatment of patients with recurrent hepatitis C after liver tansplantation or those with co-infection of HCV and HIV
    Nagahama, Hiroyasu
    Tanaka, Motohiko
    Kudo, Yohko
    Fukubayashi, Koutarou
    Takaoka, Satoru
    Ashihara, Hiroshi
    Asonuma, Katsuhiro
    Inomata, Yukihiro
    Matsushita, Shuzo
    Sasaki, Yutaka
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A217 - A217
  • [28] Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection:: indications for the investigation of new treatment approaches
    Ballesteros, AL
    Franco, S
    Fuster, D
    Planas, R
    Martínez, MA
    Acosta, L
    Sirera, G
    Salas, A
    Tor, J
    Rey-Joly, C
    Clotet, B
    Tural, C
    AIDS, 2004, 18 (01) : 59 - 66
  • [29] High interferon (IFN) daily doses in combination with ribavirin (RBV) are cost effective in the treatment of hepatitis C in HIV coinfected subjects without sustained response to interferon monotherapy.
    Puoti, M
    Zanini, B
    Quirizan, P
    Santantonio, T
    Scalise, G
    Ghinelli, F
    Chiodo, R
    Pastore, G
    Castelli, F
    HEPATOLOGY, 2002, 36 (04) : 586A - 586A
  • [30] First phase HCV kinetics in interferon and ribavirin combination therapy is an useful predictor of treatment response in chronic hepatitis C patients.
    Makiyama, A
    Itoh, Y
    Nakajima, T
    Umemura, A
    Harano, Y
    Kunimoto, K
    Okita, M
    Nakayama, M
    Mori, K
    Yamaoka, J
    Fujii, H
    Yanaguchi, K
    Yamauchi, N
    Minami, M
    Okanoue, T
    HEPATOLOGY, 2003, 38 (04) : 728A - 728A
12345